Premium
Efficacy of micafungin in pediatric immunocompromised patients with invasive fungal infection
Author(s) -
Hashii Yoshiko,
Kusuki Shigenori,
Takizawa Sachiko,
Tokimasa Sadao,
Ohta Hideaki,
Hara Junichi,
Ozono Keiichi
Publication year - 2014
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12356
Subject(s) - micafungin , medicine , echinocandin , adverse effect , antifungal , aspergillosis , candida infections , immunology , amphotericin b , dermatology , fluconazole
Abstract Background Micafungin, an antifungal echinocandin, has been indicated for pediatric patients with invasive fungal infection ( IFI ) in J apan and E urope. Its efficacy in immunocompromised pediatric patients with IFI , however, has not been fully investigated. Methods The safety and efficacy of micafungin as an antifungal therapy were analyzed in nine consecutive severe immunocompromised patients with IFI . Results Three patients with proven or probable C andida infections had complete response to micafungin therapy. Of the other six patients with proven, probable or possible A spergillus infection, four had complete response and one had partial response to micafungin treatment. No severe adverse events were observed. Conclusions In this small series, micafungin was effective for IFI caused by both C andida and A spergillus species and no severe adverse events were observed in these immunocompromised patients.